Literature DB >> 32669380

Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates.

Elizabeth C Smith1, Hunter V Brigman1, Jadyn C Anderson1, Christopher L Emery2, Tiffany E Bias3, Phillip J Bergen4, Cornelia B Landersdorfer4, Elizabeth B Hirsch5.   

Abstract

Fosfomycin has been shown to have a wide spectrum of activity against multidrug-resistant Gram-negative bacteria; however, breakpoints have been established only for Escherichia coli or Enterobacterales per the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST), respectively. A lack of additional organism breakpoints limits clinical use of this agent and has prompted extrapolation of these interpretive categories to other organisms like Pseudomonas aeruginosa without supporting evidence. Further complicating the utility of fosfomycin is the specified method for MIC determination, namely, agar dilution, which is not widely available and is both labor and time intensive. We therefore sought to determine the susceptibility of a large international collection of P. aeruginosa isolates (n = 198) to fosfomycin and to compare testing agreement rates across four methods: agar dilution, broth microdilution, disk diffusion, and Etest. Results were interpreted according to CLSI E. coli breakpoints, with 49.0 to 85.8% considered susceptible, dependent upon the testing method used. Epidemiological cutoff values were calculated and determined to be 256 μg/ml and 512 μg/ml for agar dilution and broth microdilution, respectively. Agreement rates were analyzed using both agar dilution and broth microdilution with a resulting high essential agreement rate of 91.3% between the two susceptibility testing methods. These results indicate that broth microdilution may be a reliable method for fosfomycin susceptibility testing against P. aeruginosa and stress the need for P. aeruginosa-specific breakpoints.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; agar dilution; agreement; broth microdilution; error; multidrug resistant; susceptibility testing

Mesh:

Substances:

Year:  2020        PMID: 32669380      PMCID: PMC7512173          DOI: 10.1128/JCM.01121-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

2.  Susceptibility testing quality control studies with fosfomycin tromethamine.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

3.  Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.

Authors:  Thana Khawcharoenporn; Alan Chuncharunee; Chailat Maluangnon; Thitiporn Taweesakulvashra; Pimsiri Tiamsak
Journal:  Int J Antimicrob Agents       Date:  2018-09-17       Impact factor: 5.283

4.  Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.

Authors:  Justin T Seroy; Shellee A Grim; Gail E Reid; Trevor Wellington; Nina M Clark
Journal:  J Antimicrob Chemother       Date:  2016-05-30       Impact factor: 5.790

Review 5.  Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Authors:  George G Zhanel; Courtney K Lawrence; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Michael Zhanel; Philippe R S Lagacé-Wiens; Andrew Walkty; Andrew Denisuik; Alyssa Golden; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

6.  Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model.

Authors:  Hajira Bilal; Anton Y Peleg; Michelle P McIntosh; Ian K Styles; Elizabeth B Hirsch; Cornelia B Landersdorfer; Phillip J Bergen
Journal:  J Antimicrob Chemother       Date:  2018-06-01       Impact factor: 5.790

7.  Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.

Authors:  Marina Borisova; Jonathan Gisin; Christoph Mayer
Journal:  Microb Drug Resist       Date:  2014-05-12       Impact factor: 3.431

Review 8.  Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.

Authors:  Ahmed Babiker; Lloyd Clarke; Yohei Doi; Ryan K Shields
Journal:  Diagn Microbiol Infect Dis       Date:  2019-06-24       Impact factor: 2.983

9.  Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.

Authors:  Keith S Kaye; Louis B Rice; Aaron L Dane; Viktor Stus; Olexiy Sagan; Elena Fedosiuk; Anita F Das; David Skarinsky; Paul B Eckburg; Evelyn J Ellis-Grosse
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

10.  Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.

Authors:  Natalia V Ortiz Zacarías; Anneke C Dijkmans; Jacobus Burggraaf; Johan W Mouton; Erik B Wilms; Cees van Nieuwkoop; Daan J Touw; Ingrid M C Kamerling; Jasper Stevens
Journal:  Pharmacol Res Perspect       Date:  2018-02
View more
  3 in total

Review 1.  Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales.

Authors:  Dina Zheng; Phillip J Bergen; Cornelia B Landersdorfer; Elizabeth B Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2021-11-22       Impact factor: 5.938

2.  Nucleotide substitutions in the mexR, nalC and nalD regulator genes of the MexAB-OprM efflux pump are maintained in Pseudomonas aeruginosa genetic lineages.

Authors:  Pamela Aguilar-Rodea; Gerardo Zúñiga; René Cerritos; Benjamín Antonio Rodríguez-Espino; Uriel Gomez-Ramirez; Carolina G Nolasco-Romero; Beatriz López-Marceliano; Gerardo E Rodea; Sandra Mendoza-Elizalde; Alfonso Reyes-López; Héctor Olivares Clavijo; Juan Carlos Vigueras Galindo; Norma Velázquez-Guadarrama; Irma Rosas-Pérez
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.240

Review 3.  Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections.

Authors:  Corneliu Ovidiu Vrancianu; Elena Georgiana Dobre; Irina Gheorghe; Ilda Barbu; Roxana Elena Cristian; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2021-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.